Unjha Formulations Reports Strong Financial Performance Amid Market Volatility

Unjha Formulations, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a financial trend adjustment reflecting its improved performance metrics for the quarter ending September 2025. The company reported its highest quarterly figures in several key areas: PBDIT reached Rs 0.79 crore, PBT less other income stood at Rs 0.76 crore, and PAT was recorded at Rs 0.82 crore. Additionally, the earnings per share (EPS) hit Rs 1.83, showcasing a strong operational performance.
In terms of market activity, Unjha Formulations' stock price has shown notable fluctuations, with a current price of Rs 26.00, up from a previous close of Rs 24.90. The stock has experienced a 52-week high of Rs 35.18 and a low of Rs 19.99, indicating volatility in its trading range.

When comparing the company's returns to the Sensex, Unjha Formulations has demonstrated significant growth over longer periods, with a remarkable 156.92% return over three years and an impressive 243.92% over five years. However, year-to-date and one-year returns show a decline, highlighting the challenges faced in the shorter term. Overall, the recent evaluation revision underscores the company's resilience and operational strengths amidst market fluctuations.